Association of body composition and systemic inflammation for patients with locally advanced cervical cancer following concurrent chemoradiotherapy

被引:0
|
作者
Li, Juan [1 ]
Niu, Cuili [1 ]
Zhang, Ling [1 ]
Mu, Yanmin [1 ]
Gui, Xiuyin [1 ]
机构
[1] Xingtai Third Hosp, Clin Gynecol, Xingtai, Peoples R China
来源
关键词
Cervical cancer; concurrent chemoradiotherapy; systemic inflammation; body composition; prognosis; VISCERAL FAT PERCENTAGE; PROGNOSTIC VALUE; SARCOPENIA; OBESITY; PREDICTION; MARKERS; CELLS;
D O I
10.4274/dir.2024.242751
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE Systemic inflammation and body composition are associated with survival outcomes of cancer patients. This study aimed to examine the combined prognostic value of systemic inflammatory markers and body composition parameters in patients with locally advanced cervical cancer (LACC). METHODS Patients who underwent concurrent chemoradiotherapy (CCRT) for LACC at a tertiary referral teaching hospital between January 2010 and January 2018 were enrolled. A predictive model was established based on systemic immune-inflammation index (SII) and computer tomography-derived visceral fat-to-muscle ratio (vFMR). Overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan-Meier method and Cox regression models. The model performance was assessed using discrimination, calibration, and clinical usefulness. RESULTS In total, 212 patients were enrolled. The SII and vFMR were closely related, and both independently predicted survival (P < 0.05). A predictive model was established based on the above biomarkers and included three subgroups: high-risk [both high SII (>828) and high vFMR (>1.1)], middle-risk (either high SII or high vFMR), and low-risk (neither high SII nor high vFMR). The 3-year OS (PFS) rates for low-, middle-, and high-risk patients were 90.5% (86.0%), 73.9% (58.4%), and 46.8% (36.1%), respectively (P < 0.05). This model demonstrated satisfactory predictive accuracy (area under the curve values for predicting 3-year OS and PFS were 0.704 and 0.718, respectively), good fit (Hosmer-Lemeshow tests: P > 0.05), and clinical usefulness. CONCLUSION Systemic inflammatory markers combined with body composition parameters could independently predict the prognosis of patients with LACC, highlighting the utilization of commonly collected indicators in decision-making processes.
引用
收藏
页码:279 / 290
页数:12
相关论文
共 50 条
  • [21] Concurrent chemoradiotherapy or radiotherapy alone for locally advanced cervical cancer in elderly women
    Park, Jin-hong
    Kim, Young Seok
    Ahn, Seung Do
    Choi, Eun Kyung
    Shin, Seong Soo
    Kim, Young-Tak
    Kim, Yong-Man
    Kim, Jong-Hyeok
    Yi, Seong Yoon
    Nam, Joo-Hyun
    TUMORI JOURNAL, 2010, 96 (06): : 959 - 965
  • [22] The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy
    Song, Suisui
    Rudra, Sonali
    Hasselle, Michael D.
    Dorn, Paige L.
    Mell, Loren K.
    Mundt, Arno J.
    Yamada, S. Diane
    Lee, Nita K.
    Hasan, Yasmin
    CANCER, 2013, 119 (02) : 325 - 331
  • [23] Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
    Byun, Sang Jun
    Kim, Jin Hee
    Kim, Ok Bae
    Song, Hong Suk
    RADIATION ONCOLOGY JOURNAL, 2011, 29 (01): : 20 - 27
  • [24] Comparison of Concurrent Cisplatin Chemoradiotherapy Plus Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy Alone in Locally Advanced Cervical Cancer
    Chen, S.
    Ren, T.
    Wang, X.
    Shen, Y.
    Ning, X.
    He, H.
    Feng, C.
    Yin, P.
    Huang, H.
    Yue, N. J.
    Zhang, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S52 - S52
  • [25] Concurrent Chemoradiotherapy Increases the Levels of Soluble Immune Checkpoint Proteins in Patients with Locally Advanced Cervical Cancer
    Liu, Chao
    Li, Xiaohui
    Li, Aijie
    Zou, Wenxue
    Huang, Rui
    Hu, Xiaoyu
    Yu, Jinming
    Zhang, Xiaoling
    Yue, Jinbo
    JOURNAL OF IMMUNOLOGY RESEARCH, 2022, 2022
  • [26] Prognostic value of Naples prognostic score in locally advanced cervical cancer patients undergoing concurrent chemoradiotherapy
    Zhang, Xiaojun
    Gu, Mengxuan
    Zhu, Jiahao
    Gu, Ruike
    Yang, Bo
    Ji, Shengjun
    Zhao, Yutian
    Gu, Ke
    BIOMOLECULES AND BIOMEDICINE, 2024,
  • [27] Patterns of Treatment Failure after Concurrent Chemoradiotherapy or Adjuvant Radiotherapy in Patients with Locally Advanced Cervical Cancer
    Wang, Yifei
    Zhang, Tao
    Peng, Siyun
    Zhou, Rui
    Li, Longhao
    Kou, Lingna
    Yuan, Mingyang
    Li, Minmin
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (03) : 75 - 82
  • [28] Concurrent Chemoradiotherapy Increases the Levels of Soluble Immune Checkpoint Proteins in Patients with Locally Advanced Cervical Cancer
    Liu, C.
    Li, A.
    Hu, X.
    Zou, W.
    Yu, J.
    Zhang, X.
    Yue, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S113 - S113
  • [29] CONCURRENT NEOADJUVANT CHEMORADIOTHERAPY WITH CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
    Liu, M.
    Chen, C.
    Jian, J.
    Kuo, L.
    Chern, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 142 - 142
  • [30] The therapeutic value of adjuvant chemotherapy after concurrent chemoradiotherapy for locally advanced cervical cancer
    Wang, Ya-nan
    Zhong, Mei-ling
    Liang, Mei-rong
    Yang, Jian-tong
    Zeng, Si-yuan
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2023, 88 (05) : 286 - 293